drugset / Trial / NCT05429008
A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
NaSingle-groupOpen-labelOther
Summary
This is an open-label, first-in-human (FIH) Phase I study to evaluate the safety, tolerability, and preliminary efficacy of a humanized anti-CD47 monoclonal antibody (HMPL-A83) in patients with advanced malignant neoplasm.
Timeline
- Start
- 2022-07-15
- Primary completion
- 2025-04-07
- Completion
- 2025-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HMPL-A83 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | HMPL-A83 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | HMPL-A83 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | HMPL-A83 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | HMPL-A83 | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | HMPL-A83 | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | HMPL-A83 | Monoclonal antibody | 45 mg/kg | Intravenous |